DoD Scleroderma, Idea Development Award


Funding Opportunity ID: 333548
Opportunity Number: W81XWH-21-SRP-IDA
Opportunity Title: DoD Scleroderma, Idea Development Award
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
CFDA Number(s): 12.420
Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:
Agency Code: DOD-AMRAA
Agency Name: Department of Defense
Dept. of the Army — USAMRAA
Posted Date: May 14, 2021
Close Date: Aug 25, 2021
Last Updated Date: May 14, 2021
Award Ceiling: $0
Award Floor: $0
Estimated Total Program Funding: $1,920,000
Expected Number of Awards: 3
Description: The IDA promotes ideas that are still in the early stages of development and have the potential to yield high-impact findings and new avenues of investigation. This award mechanism supports conceptually innovative high-risk/high-reward research that could lead to critical discoveries or major advancements in scleroderma research and/or improvements in patient care. Research projects should include a well-formulated, testable hypothesis based on strong preliminary data and scientific rationale.New Investigator Collaboration Option: The FY21 SRP IDA mechanism encourages applications in which a New Investigator in the early stages of their career partners with an established scleroderma researcher (as demonstrated by current funding and recent publications). The New Investigator Collaboration Option is designed to support the continued development of promising independent investigators that are early in their faculty appointments. All New Investigators must meet specific eligibility criteria as described in Section II.C, Eligibility Information. If the New Investigator Collaboration Option is selected, one PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The Initiating PI must be a New Investigator. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. If recommended for funding, each PI will be named to an individual award within the recipient organization. For individual submission requirements for the Initiating and Partnering PIs, refer to Section II.D.2, Content and Form of the Application Submission.The following are significant features of the FY21 SRP IDA:• Preliminary Data: Preliminary data are required but need not be from the scleroderma research field. Preliminary data may include unpublished or published results from the laboratory of the PI or collaborators named on the application and/or data from the published literature relevant to scleroderma.• Impact: The application should describe the potential short-term impact of the research project toward improving the understanding of the causes and progression of scleroderma and/or realizing improvements in patient care and/or quality of life. High impact research will, if successful, have the potential to generate critical discoveries or major advancements in scleroderma research and ultimately lead to improvements in patient care.• Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities that may include high-risk/potentially high-gain approaches to scleroderma research. Research that is merely an incremental advancement (the next logical step) is not considered innovative.• Relevance to Military Health: The SRP seeks to support research that is relevant to the healthcare needs of military Service Members, Veterans, and their families. Relevance to military health will be considered in determining relevance to the mission of the Defense Health Program (DHP) and FY21 SRP during programmatic review. Investigators are encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health:○ Use of military or Veteran populations, biospecimens, data/databases, or programs in the proposed research○ Collaboration with Department of Defense (DOD) or Department of Veterans Affairs (VA) investigators○ Involvement of military consultants (Army, Air Force) or specialty leaders (Navy, Marine Corps) to the Surgeons General in a relevant specialty area○ Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population○ Explanation of how the project addresses an aspect of scleroderma that has direct relevance to military Service Members, Veterans, or other Military Health System beneficiaries, including environmental exposuresSubmissions from and partnerships with investigators at DOD military treatment facilities and laboratories, and VA medical centers and research laboratories are encouraged.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public.The types of awards made under the program announcement will be assistance agreements. An assistance agreement is appropriate when the federal government transfers a “thing of value” to a “state, local government,” or “other recipient” to carry out a public purpose of support or stimulation authorized by a law of the United States instead of acquiring property or service for the direct benefit and use of the U.S. government. An assistance agreement can take the form of a grant or cooperative agreement. The level of involvement on the part of the DOD during project performance is the key factor in determining whether to award a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305), and the award will identify the specific substantial involvement. Substantial involvement may include, but is not limited to, collaboration, participation, or intervention in the research to be performed under the award. The award type, along with the start date, will be determined during the negotiation process.The anticipated direct costs budgeted for the entire period of performance for an FY21 SRP IDA will not exceed $300,000 for an application with a single PI or $450,000 if applying under the New Investigator Collaboration Option. At least fifty percent of the direct budget costs must be allocated to the New Investigator. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards will be made no later than September 30, 2022. For additional information refer to Section II.F.1, Federal Award Notices.The CDMRP expects to allot approximately $1.92M to fund approximately one IDA application and two IDA – New Investigator Collaboration Option applications. Funding of applications received is contingent upon the availability of federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY21 funding opportunity will be funded with FY21 funds, which will expire for use on September 30, 2027.
Version: 1

Visit the Official Webpage For More Details on DoD Scleroderma, Idea Development Award


Please enter your comment!
Please enter your name here